| Schedule of non-controlling interests in consolidated entities |
Non-controlling interests in consolidated entities are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended
|
|
|
|
|
|
|
|
|
|
As of March 31, 2020
|
|
March 31, 2020
|
|
|
As of March 31, 2020
|
|
|
|
|
|
|
|
|
|
Net loss attributable to
|
|
non-controlling interests
|
|
Non-controlling
|
|
|
($ in thousands)
|
|
NCI equity share
|
|
Non-controlling interests
|
|
in consolidated entities
|
|
ownership
|
|
|
Aevitas
|
|
$
|
(1,989)
|
|
$
|
(186)
|
|
$
|
(2,175)
|
|
35.8
|
%
|
|
Avenue 2
|
|
|
5,419
|
|
|
(955)
|
|
|
4,464
|
|
77.3
|
%
|
|
Baergic
|
|
|
(1,201)
|
|
|
(3)
|
|
|
(1,204)
|
|
33.0
|
%
|
|
Cellvation
|
|
|
(917)
|
|
|
(38)
|
|
|
(955)
|
|
20.6
|
%
|
|
Checkpoint 1
|
|
|
15,121
|
|
|
(2,403)
|
|
|
12,718
|
|
78.4
|
%
|
|
Coronado SO
|
|
|
(290)
|
|
|
-
|
|
|
(290)
|
|
13.0
|
%
|
|
Cyprium
|
|
|
(795)
|
|
|
(89)
|
|
|
(884)
|
|
18.9
|
%
|
|
Helocyte
|
|
|
(4,700)
|
|
|
(165)
|
|
|
(4,865)
|
|
18.8
|
%
|
|
JMC
|
|
|
118
|
|
|
159
|
|
|
277
|
|
6.9
|
%
|
|
Mustang 2
|
|
|
39,640
|
|
|
(8,008)
|
|
|
31,632
|
|
69.0
|
%
|
|
Tamid
|
|
|
(651)
|
|
|
(10)
|
|
|
(661)
|
|
22.8
|
%
|
|
Total
|
|
$
|
49,755
|
|
$
|
(11,698)
|
|
$
|
38,057
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the twelve months ended
|
|
|
|
|
|
|
|
|
|
As of December 31, 2019
|
|
|
December 31, 2019
|
|
|
As of December 31, 2019
|
|
|
|
|
|
|
|
|
Net loss attributable to
|
|
non-controlling interests
|
|
Non-controlling
|
|
|
($ in thousands)
|
|
NCI equity share
|
|
Non-controlling interests
|
|
in consolidated entities
|
|
ownership
|
|
|
Aevitas
|
|
$
|
(1,249)
|
|
$
|
(694)
|
|
$
|
(1,943)
|
|
35.8
|
%
|
|
Avenue 2
|
|
|
24,269
|
|
|
(19,011)
|
|
|
5,258
|
|
77.3
|
%
|
|
Baergic
|
|
|
23
|
|
|
(1,162)
|
|
|
(1,139)
|
|
33.0
|
%
|
|
Cellvation
|
|
|
(732)
|
|
|
(158)
|
|
|
(890)
|
|
20.6
|
%
|
|
Checkpoint 1
|
|
|
29,389
|
|
|
(14,687)
|
|
|
14,702
|
|
78.0
|
%
|
|
Coronado SO
|
|
|
(290)
|
|
|
-
|
|
|
(290)
|
|
13.0
|
%
|
|
Cyprium
|
|
|
(320)
|
|
|
(99)
|
|
|
(419)
|
|
10.6
|
%
|
|
Helocyte
|
|
|
(4,322)
|
|
|
(402)
|
|
|
(4,724)
|
|
19.3
|
%
|
|
JMC
|
|
|
(211)
|
|
|
325
|
|
|
114
|
|
6.9
|
%
|
|
Mustang 2
|
|
|
62,025
|
|
|
(25,727)
|
|
|
36,298
|
|
70.3
|
%
|
|
Tamid
|
|
|
(565)
|
|
|
(85)
|
|
|
(650)
|
|
22.8
|
%
|
|
Total
|
|
$
|
108,017
|
|
$
|
(61,700)
|
|
$
|
46,317
|
|
|
|
Note 1: Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.
Note 2: Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.
|